Hand-held, dilation-free, electroretinography in children under 3 years of age treated with vigabatrin
This is the first study to assess the utility of RETeval device in children under 3 years of age undergoing vigabatrin treatment.
LKC’s RETeval™ demonstrated high intra-visit reliability with responses consistent with the standard Espion ERG and may be beneficial for assessment of retinal toxicity in young children treated with vigabatrin.
Warning: This product can expose you to chemicals including lead, which is known to the State of California to cause cancer and birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.
Substance Tables:
The table below lists substances which may be contained within LKC’s RETeval and RETevet products. Substances listed as Type 1 are within permissible levels in one or more of LKC’s products. Substances listed as Type 2 are used in the production of some components used in LKC products and may be present at trace levels, but are typically destroyed during processing.